Am J Psychiatry

1. DE LAS CUEVAS C
   Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia.
   Am J Psychiatry. 2026;183:269-270.
   

   >> Share

   
   
2. NICHOLSON RC, Choi UE, Mojtabai R, Thrul J, et al
   Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.
   Am J Psychiatry. 2026;183:260-268.
   

   >> Share

   
   

   
   J Clin Psychiatry

3. SCANLON F, Mueser KT, Cather C
   Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis.
   J Clin Psychiatry. 2026;87:25m15991.
   

   >> Share

   
   
4. 
   Correction. The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia.
   J Clin Psychiatry. 2026;87:26lcx16443.
   

   >> Share

   
   

   
   J Clin Psychopharmacol

5. GROVER S, Yadav N, Sutail H, Chakrabarti S, et al
   Hepatic Steatosis, Hepatic Fibrosis, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Schizophrenia Patients: An Exploratory Study From India.
   J Clin Psychopharmacol. 2026 Apr 3. doi: 10.1097/JCP.0000000000002159.
   

   >> Share

   
   
6. CALLI SY, Fidan YS, Kizilsert A, Izci F, et al
   Comparison of Standard and Two-Injection Start Regimens of Long-Acting Injectable Aripiprazole Monohydrate in Female Patients With Schizophrenia and Bipolar Disorder: A Retrospective Cohort Study.
   J Clin Psychopharmacol. 2026 Apr 2. doi: 10.1097/JCP.0000000000002183.
   

   >> Share

   
   

   
   Mol Psychiatry

7. DAI SS, Dang X, Gong D, Li D, et al
   Molecular regulatory mechanisms of schizophrenia-associated functional non-coding variants.
   Mol Psychiatry. 2026 Apr 2. doi: 10.1038/s41380-026-03566.
   

   >> Share

   
   
8. TANAKA R, Liao J, Liu Y, Zhu W, et al
   Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia.
   Mol Psychiatry. 2026 Apr 1. doi: 10.1038/s41380-026-03567.
   

   >> Share

   
   
9. ETYEMEZ S, Sivananthan R, Faria AV, Iasevoli F, et al
   Brain structural abnormalities in treatment-resistant schizophrenia.
   Mol Psychiatry. 2026 Mar 28. doi: 10.1038/s41380-026-03558.
   

   >> Share

   
   

   
   Schizophr Res

10. FRENCH C, Sawyer C, Fabian H, Hassan L, et al
    The Remote Exercise And Lifestyle (REAL) intervention for first-episode psychosis: feasibility and preliminary effects of online group fitness training.
    Schizophr Res. 2026;293:58-66.
    

    >> Share

    
    
11. SAARIKIVI J, Hjellvik V, Tiihonen J, Lahteenvuo M, et al
    Predicting future mortality risk in first-episode psychosis: External validation of the MIRACLE-FEP machine learning model.
    Schizophr Res. 2026;292:116-123.
    

    >> Share

    
    
12. ANDERSEN NK, Fagerlund B, Jepsen JRM, Hjorthoj C, et al
    Factors associated with employment and hospitalizations in early-onset psychosis: a clinical study with register-based follow-up.
    Schizophr Res. 2026;293:48-57.
    

    >> Share

    
    
13. PAN A, Yuan K, Xiu M, Guan X, et al
    Sleep-architecture signatures for differential diagnosis of schizophrenia, bipolar, and major depressive disorders: A polysomnography-based multinomial modeling study.
    Schizophr Res. 2026;293:39-47.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share